Patents by Inventor Mark R. Hurtt

Mark R. Hurtt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDES FOR PREVENTING OR TREATING A DISEASE OR DISORDER ASSOCIATED WITH CBP OR p300 MISREGULATION, AND METHODS FOR USE AND IDENTIFICATION THEREOF
    Publication number: 20120302503
    Abstract: Described herein are therapeutic peptides composed of a cell penetrating peptide, a peptide derived from the sequence of c-Myb, and a peptide derived from the sequence of CREB, useful for the treatment or prevention of a disease or disorder associated with CBP or p300 misregulation.
    Type: Application
    Filed: May 7, 2012
    Publication date: November 29, 2012
    Applicant: AML Therapeutics, LLC
    Inventor: Mark R. Hurtt
  • Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
    Patent number: 8133861
    Abstract: Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic brain injury, cerebral aneurism, spinal cord injury and the like).
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: March 13, 2012
    Assignee: Alseres Pharmaceuticals, Inc.
    Inventors: Noel James Cusack, Mark R. Hurtt, Richard M. Thorn
  • SYSTEMIC PURINE ADMINISTRATION: MODULATING AXONAL OUTGROWTH OF CENTRAL NERVOUS SYSTEM NEURONS
    Publication number: 20090221521
    Abstract: Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic brain injury, cerebral aneurism, spinal cord injury and the like).
    Type: Application
    Filed: February 26, 2009
    Publication date: September 3, 2009
    Applicant: Alseres Pharmaceuticals, Inc.
    Inventors: Mark R. Hurtt, Noel James Cusack, Richard M. Thorn